Hong Kong Pharmaceuticals Stock News

Greentown China Holdings (SEHK:3900) has issued unaudited guidance indicating an expected 95% drop in 2025 profit attributable to owners, citing thinner gross margins, weaker joint venture contributions, and fresh asset impairment charges. See our latest analysis for Greentown China Holdings. The latest guidance lands after a period of mixed performance, with a 90 day share price return of 28.67% and a year to date share price return of 29.59%, but a 1 year total shareholder return of a...

Zhejiang Leapmotor Technology (SEHK:9863) just reported full year 2025 earnings, turning a loss into profit as sales reached CNY 64,731.86 million and net income came in at CNY 538.39 million. See our latest analysis for Zhejiang Leapmotor Technology. The latest earnings release comes after a period of mixed performance, with a 7 day share price return of 8.84% contrasting with a year to date share price return decline of 10.09% and a 3 year total shareholder return of 49.78%. This suggests...

Why Sichuan Baicha Baidao Industrial is in focus now Sichuan Baicha Baidao Industrial (SEHK:2555) has issued unaudited earnings guidance for 2025, flagging higher adjusted net profit and net profit compared with 2024, which puts its profitability and recent share performance under the spotlight for investors. See our latest analysis for Sichuan Baicha Baidao Industrial. The earnings guidance has arrived after a weak stretch for investors, with a 1 year total shareholder return decline of...

China Tobacco International (HK) (SEHK:6055) has caught investor attention after reporting full year 2025 results, alongside a proposed final cash dividend of HK$0.33 per share, pairing earnings information with a fresh income timeline. See our latest analysis for China Tobacco International (HK). The latest earnings and dividend news comes after a mixed price pattern, with a 1-day share price return of 1.41% against a 30-day share price return decline of 15.29%, yet a 1-year total...

Angelalign Technology (SEHK:6699) has issued fresh 2025 earnings guidance, projecting net profit of about US$24 million to US$30 million, compared with roughly US$10 million in 2024, highlighting stronger clear aligner demand and cost timing effects. See our latest analysis for Angelalign Technology. Angelalign Technology's shares have rallied in recent months, with a 90 day share price return of 17.51% and year to date share price return of 16.26%. However, the 3 year total shareholder...

Akeso (SEHK:9926) is back in focus after announcing that its trispecific antibody AK150 has received IND clearance from China’s NMPA, clearing the way for clinical trials in advanced solid tumors. See our latest analysis for Akeso. The AK150 IND clearance, together with recent cervical cancer data for cadonilimab and the GBM collaboration announcement, has coincided with a 5.81% 1 day share price return and a 12.44% 7 day share price return at a current share price of HK$116.6. The 1 year...

InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader to reach trials in China and only the second globally. This move positions InnoCare at the forefront of a new class of targeted immunology drugs, in an area where no VAV1-focused therapies are yet approved worldwide. We’ll now examine how advancing ICP-538, a first-in-China VAV1 degrader, could...

Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the group. See our latest analysis for Keymed Biosciences. The CMG901 Phase III update comes after a strong 1 year total shareholder return of 50.97%. Shorter term share price momentum is steadier, with a 7 day share price return of 6.36% around the HK$54.35 level. If you are looking for other...

China Mengniu Dairy (SEHK:2319) has issued preliminary 2025 guidance flagging a 7% to 8% revenue decline and a slightly lower operating margin, while also being removed from the Hang Seng China Enterprises Index. See our latest analysis for China Mengniu Dairy. The latest guidance and index removal come after a mixed share price pattern, with a 12.1% year to date share price return and a 12.5% 90 day share price return, but a 13.0% negative total shareholder return over the past year. This...

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved phase 1 trials for two solid tumour candidates, HLX316 and HLX3901, both backed by positive preclinical safety and efficacy data. See our latest analysis for Shanghai Henlius Biotech. The recent NMPA green light for HLX316 and HLX3901 comes as Shanghai Henlius Biotech’s share price sits at HK$67.95, with a 90 day share price return of 13.53% and a very large 3 year...

Genscript Biotech has reported its full-year 2025 results, with sales rising to US$959.53 million while the company moved from a prior-year net income of US$2.96 billion to a net loss of US$532.83 million, alongside higher basic and diluted losses per share. A key driver of this sharp swing in reported profitability is the absence of the previous year’s very large one-time unrealised gain from deconsolidation, which means the latest figures chiefly reflect the underlying operating profile...

Guotai Junan International Holdings (SEHK:1788) has called a board meeting for 25 March 2026 to approve its audited 2025 results and consider a potential dividend, putting capital allocation and shareholder returns in focus. See our latest analysis for Guotai Junan International Holdings. The upcoming board meeting comes after a softer patch for the share price, with a 30 day share price return of a 13.9% decline and a year to date share price return of a 3.8% decline, set against a very...

Dongfeng Motor Group (SEHK:489) has just been dropped from the FTSE All-World Index (USD). This index change can affect how some global funds treat the stock in their portfolios. See our latest analysis for Dongfeng Motor Group. Recent moves in Dongfeng Motor Group’s share price have been mixed, with an 8.4% 90 day share price return alongside a very large 3 year total shareholder return of about 3x. This suggests longer term momentum remains strong even as the latest index change and...

Guoquan Food (Shanghai) (SEHK:2517) has attracted fresh attention after reporting full year 2025 results alongside a proposed final dividend, bringing together profit figures, cash return details and expansion plans in a single news cycle. See our latest analysis for Guoquan Food (Shanghai). The share price is now at HK$3.85, with a 1-day share price return of 0.79% and a 7-day share price return of 3.49%. The 90-day share price return of 13.91% and 1-year total shareholder return of 111.77%...

Flash Charging launch puts BYD stock in focus BYD (SEHK:1211) is drawing fresh investor attention after unveiling its FLASH Charging system and Blade Battery 2.0, as well as new models such as the DENZA Z9GT and Seal 6 Super Hybrid across key international markets. See our latest analysis for BYD. Despite the buzz around FLASH Charging and new model launches, BYD’s share price at HK$96.75 has a year-to-date share price return decline of 2.03% and a 1-year total shareholder return decline of...

FIH Mobile (SEHK:2038) has just posted its FY 2025 second half results, with revenue of US$4.6b, net income of US$46.6m and basic EPS of US$0.06. This sets the tone for a year where the trailing 12 month figures show revenue of US$6.7b and net income of US$52.7m converting into EPS of US$0.07. The company has seen revenue move from US$3.8b in the second half of 2024 to US$4.6b in the latest half, while basic EPS shifted from US$0.01 to US$0.06, giving investors a clearer read on how sales are...

Bloks Group (SEHK:325) has just posted its FY 2025 numbers, with second half revenue of C¥1.6b and basic EPS of C¥1.36. Trailing twelve month revenue sits at C¥2.9b and EPS at C¥2.58, all backed by C¥633.7m of net income excluding extra items. The company has seen revenue move from C¥1.2b and a net loss of C¥143.2m in 2H 2024 to C¥1.6b and net income of C¥337.2m in 2H 2025. This shift puts profitability and earnings quality firmly in focus for investors looking at how margins are shaping...

New Silkroad Culturaltainment (SEHK:472) has released its FY 2025 numbers with first half revenue of HK$213.44 million and a basic EPS loss of HK$0.013008, while trailing 12 month figures show revenue of HK$374.72 million and a basic EPS loss of HK$0.0845. Over recent periods, the company has seen revenue move between HK$232.09 million and HK$149.90 million, with basic EPS ranging from small profits of about HK$0.0003 to HK$0.0007 per share. The latest trailing 12 month view shows a return to...

Zhejiang Leapmotor's recent pre-earnings update, ahead of its 16 March 2026 results, has drawn investor attention to margin trends, electric vehicle deliveries, and free cash flow strength as key indicators of its current operating health. This heightened focus on revenue per unit, gross margin quality, and management guidance on volumes and pricing puts Leapmotor’s underlying unit economics and cash generation firmly in the spotlight. We’ll now examine how this intensified focus on...

Why Lepu Biopharma’s Latest Guidance Matters Lepu Biopharma (SEHK:2157) has drawn fresh attention after issuing earnings guidance that points to at least RMB 200 million in net profit for 2025, compared with a RMB 411 million loss in 2024. The company links this projected swing to revenue from PUYOUHENG and newly approved MEIYOUHENG, expanded licensing income, and a one off reclassification gain on an investment, while an upcoming March 25 board meeting will review the full 2025 results and...

On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing. This IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis. We will now examine...

Context for Shanghai Junshi Biosciences after recent share performance Shanghai Junshi Biosciences (SEHK:1877) has seen mixed share performance recently, with a small gain over the past week but declines over the past month and past 3 months, drawing attention to how its fundamentals line up. For investors tracking the stock longer term, the shares show a negative total return over 3 and 5 years, while the 1 year total return is positive. This can make current pricing and expectations...

Oshidori International Holdings (SEHK:622) issued new earnings guidance pointing to a net profit of HK$171.4 million for 2025, compared with a HK$194.7 million loss in 2024. This highlights a sharp swing in reported performance. See our latest analysis for Oshidori International Holdings. The guidance appears to sit against very strong recent momentum, with a 30 day share price return of 45.45% and a 90 day gain of 120%, while the 1 year total shareholder return of 266.67% points to sustained...

What recent performance says about Alphamab Oncology Alphamab Oncology (SEHK:9966) has seen mixed share price performance recently, with a 0.6% move over the past day and around 9.6% over the past week, but negative returns over the month and the past 3 months. See our latest analysis for Alphamab Oncology. With the share price at HK$8.6, Alphamab Oncology’s recent 7 day share price return of 9.6% sits against a 30 day decline of 3.4% and a 90 day decline of 19.8%. The 1 year total...